Furthermore, cyclin D1 and CDK 4 are able to guide cell proliferation also in an ER-independent manner.9 Given these data, pharmacological inhibition of CDK 4/6 represents an appealing and interesting therapeutic strategy to treat HR-positive BC. The gene discussed is CCND1; the disease is breast cancer.